Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Ratjen

Showing results (251-260 of 326) with videos related to

Pageof 33
Sort By:
Chest|September 9, 2010
Exhaled nitric oxide in pulmonary diseases: a comprehensive reviewPeter J Barnes, Raed A Dweik, Arthur F Gelb, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 15, 2026
Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudyNicole Green, Phuong Vu, Jing Xie, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 14, 2011
Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patientsHarriet Corvol, Julie Beucher, Pierre-Yves Boëlle, et al.
The Lancet. Respiratory Medicine|October 15, 2014
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)Edward F McKone, Drucy Borowitz, Pavel Drevinek, et al.
Pediatric Neurology|April 17, 2024
De Novo Brain Vascular Malformations in Hereditary Hemorrhagic TelangiectasiaLauren A Beslow, Timo Krings, Helen Kim, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 18, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension studyJennifer L Goralski, Cori Daines, Jessica E Pittman, et al.
Annals of the American Thoracic Society|June 20, 2025
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6 to 11-Year-Olds with Cystic FibrosisJessica E Pittman, Sarah Morgan, Morgan McCreary, et al.
The European Respiratory Journal|July 11, 2015
Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbationsNicole Sonneveld, Sanja Stanojevic, Reshma Amin, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 3, 2014
Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patientsYvonne C W Yau, Felix Ratjen, Elizabeth Tullis, et al.
Physiological Reports|May 26, 2022
Non-invasive MR imaging techniques for measuring femoral arterial flow in a pediatric and adolescent cohortJessica E Caterini, Kate Rendall, Barbara Cifra, et al.
Pageof 33

Showing results (251-260 of 326) with videos related to

Sort By:
Pageof 33
Chest|September 9, 2010
Exhaled nitric oxide in pulmonary diseases: a comprehensive reviewPeter J Barnes, Raed A Dweik, Arthur F Gelb, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 15, 2026
Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudyNicole Green, Phuong Vu, Jing Xie, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 14, 2011
Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patientsHarriet Corvol, Julie Beucher, Pierre-Yves Boëlle, et al.
The Lancet. Respiratory Medicine|October 15, 2014
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)Edward F McKone, Drucy Borowitz, Pavel Drevinek, et al.
Pediatric Neurology|April 17, 2024
De Novo Brain Vascular Malformations in Hereditary Hemorrhagic TelangiectasiaLauren A Beslow, Timo Krings, Helen Kim, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 18, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension studyJennifer L Goralski, Cori Daines, Jessica E Pittman, et al.
Annals of the American Thoracic Society|June 20, 2025
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6 to 11-Year-Olds with Cystic FibrosisJessica E Pittman, Sarah Morgan, Morgan McCreary, et al.
The European Respiratory Journal|July 11, 2015
Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbationsNicole Sonneveld, Sanja Stanojevic, Reshma Amin, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 3, 2014
Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patientsYvonne C W Yau, Felix Ratjen, Elizabeth Tullis, et al.
Physiological Reports|May 26, 2022
Non-invasive MR imaging techniques for measuring femoral arterial flow in a pediatric and adolescent cohortJessica E Caterini, Kate Rendall, Barbara Cifra, et al.
Pageof 33